140 related articles for article (PubMed ID: 33605014)
1. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Okabe N; Mine H; Takagi H; Watanabe M; Muto S; Matsumura Y; Shio Y; Suzuki H
Thorac Cancer; 2021 Apr; 12(7):1141-1144. PubMed ID: 33605014
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L
Front Immunol; 2020; 11():607416. PubMed ID: 33584678
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.
Inaba-Higashiyama R; Yoshida T; Jo H; Shirasawa M; Motoi N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3618-3621. PubMed ID: 33085191
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
5. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
6. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; Filetti M; Pizzutilo P; Russano M; Citarella F; Cantini L; Targato G; Nigro O; Ferrara MG; Buti S; Scodes S; Landi L; Guaitoli G; Della Gravara L; Tabbò F; Ricciardi S; De Toma A; Friedlaender A; Petrelli F; Addeo A; Porzio G; Ficorella C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077515
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response.
Yamasaki M; Matsumoto Y; Nakamoto K; Hattori N
J Cancer Res Ther; 2021; 17(6):1580-1582. PubMed ID: 34916402
[TBL] [Abstract][Full Text] [Related]
11. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
15. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
18. Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report.
Medusa PM; Gilli M; Notizia L; Pagliaro R; Carro N; Moriello A; D'Agnano V; Bianco A; Perrotta F; Vitiello F
Monaldi Arch Chest Dis; 2022 Nov; 93(4):. PubMed ID: 36426899
[TBL] [Abstract][Full Text] [Related]
19. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Matsumoto H; Hirano K; Kominami R; Tomii K; Suzuki H; Hirashima T; Tanaka S; Uchida J; Morita M; Kanazu M; Mori M; Nagata K; Fukuda I; Tamiya M
BMC Cancer; 2021 Apr; 21(1):346. PubMed ID: 33794809
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
